Jasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) saw a significant decline in short interest in March. As of March 15th, there was short interest totalling 1,670,000 shares, a decline of 19.7% from the February 28th total of 2,080,000 shares. Based on an average daily volume of 526,700 shares, the short-interest ratio is presently 3.2 days. Currently, 14.1% of the shares of the company are short sold.
Analysts Set New Price Targets
A number of analysts have commented on JSPR shares. HC Wainwright restated a "buy" rating and issued a $40.00 price target on shares of Jasper Therapeutics in a research report on Tuesday, March 11th. JMP Securities restated a "market outperform" rating and set a $70.00 target price on shares of Jasper Therapeutics in a research note on Monday, January 6th. BMO Capital Markets initiated coverage on shares of Jasper Therapeutics in a research report on Friday, December 6th. They issued an "outperform" rating and a $63.00 price target for the company. UBS Group assumed coverage on shares of Jasper Therapeutics in a research note on Thursday, February 13th. They issued a "buy" rating and a $38.00 price objective for the company. Finally, Royal Bank of Canada lowered their target price on shares of Jasper Therapeutics from $68.00 to $48.00 and set an "outperform" rating on the stock in a research note on Thursday, January 9th. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $62.50.
Check Out Our Latest Research Report on JSPR
Jasper Therapeutics Trading Down 5.0 %
Shares of NASDAQ:JSPR traded down $0.20 during midday trading on Friday, reaching $3.81. 222,875 shares of the company were exchanged, compared to its average volume of 279,550. The stock has a market cap of $57.23 million, a PE ratio of -0.80 and a beta of 2.23. The business's fifty day moving average is $5.52 and its two-hundred day moving average is $14.20. Jasper Therapeutics has a one year low of $3.65 and a one year high of $30.70.
Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($1.62) EPS for the quarter, missing the consensus estimate of ($1.27) by ($0.35). As a group, sell-side analysts expect that Jasper Therapeutics will post -4.47 EPS for the current year.
Hedge Funds Weigh In On Jasper Therapeutics
Institutional investors have recently added to or reduced their stakes in the company. Boxer Capital Management LLC purchased a new stake in shares of Jasper Therapeutics during the 4th quarter worth approximately $7,483,000. Integral Health Asset Management LLC raised its stake in Jasper Therapeutics by 85.7% during the fourth quarter. Integral Health Asset Management LLC now owns 650,000 shares of the company's stock valued at $13,897,000 after purchasing an additional 300,000 shares in the last quarter. Braidwell LP raised its stake in Jasper Therapeutics by 47.9% during the fourth quarter. Braidwell LP now owns 714,658 shares of the company's stock valued at $15,279,000 after purchasing an additional 231,358 shares in the last quarter. Soleus Capital Management L.P. lifted its position in Jasper Therapeutics by 11.2% during the fourth quarter. Soleus Capital Management L.P. now owns 1,494,420 shares of the company's stock valued at $31,951,000 after purchasing an additional 150,755 shares during the last quarter. Finally, Stempoint Capital LP purchased a new position in shares of Jasper Therapeutics in the 4th quarter worth $2,892,000. Hedge funds and other institutional investors own 79.85% of the company's stock.
Jasper Therapeutics Company Profile
(
Get Free Report)
Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.
Further Reading
Before you consider Jasper Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jasper Therapeutics wasn't on the list.
While Jasper Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
